<DOC>
	<DOCNO>NCT00244959</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use anastrozole may fight breast cancer lower amount estrogen body make . PURPOSE : This phase II trial study anastrozole effect postmenopausal woman undergone surgery ductal carcinoma situ stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Anastrozole Treating Postmenopausal Women With DCIS Stage I-III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 12-month change breast density postmenopausal woman ductal carcinoma situ ( DCIS ) stage I-III breast cancer treat adjuvant anastrozole . Secondary - Determine change estrone sulfate level patient treat drug . - Correlate change breast density change circulate estrone sulfate level patient treat drug . - Determine frequency polymorphism aromatase ( CYP19 ) evaluate relationship wild-type aromatase enzyme change breast density change estrone sulfate level patient treat drug . - Determine 12-month change bone density , correlate change circulate estrone sulfate level patient treat drug . - Correlate reversal hypermethylation change circulate estrone sulfate level breast density patient treat drug . OUTLINE : This pilot study . Patients stratify accord concurrent bisphosphonate use ( yes v ) . Patients receive oral anastrozole daily 12 month absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer meet 1 follow criterion : Ductal carcinoma situ ( DCIS ) Invasive carcinoma Stage IIII disease Must undergone breast cancer surgery within past 6 month , include follow : Mastectomy lumpectomy without radiation Sentinel node and/or axillary node dissection Reexcision lumpectomy margin Intact contralateral breast No prior radiation therapy mastectomy Prior biopsy allow Hormone receptor status : Estrogen and/or progesterone receptorpositive tumor immunohistochemical staining PATIENT CHARACTERISTICS : Sex Female Menopausal status Postmenopausal , define 1 following : At least 60 year age Less 60 year age amenorrheic ≥ 12 month prior study entry Less 60 year age , amenorrheic &lt; 12 month prior day 1 , luteinizing hormone ( LH ) follicle stimulate hormone ( FSH ) value within postmenopausal range Less 60 year age , without uterus , LH FSH value within postmenopausal range Underwent prior bilateral oophorectomy Underwent prior radiation castration AND amenorrheic ≥ 6 month Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Chemotherapy No prior concurrent adjuvant chemotherapy breast cancer Endocrine therapy No prior aromatase inhibitor At least 6 week since prior concurrent tamoxifen At least 6 week since prior concurrent hormone replacement therapy Concurrent lowdose , local vaginal estrogen form either conjugate estrogen ring similar product ( e.g. , Estring® Vagifem® ) allow At least 6 week since prior concurrent selective estrogen receptor modulators ( e.g. , raloxifene ) Radiotherapy See Disease Characteristics Surgery See Disease Characteristics No contralateral breast implant Other Concurrent bisphosphonates allow discretion treat oncologist No concurrent consumption soy supplement Concurrent routine dietary consumption soycontaining food allow No concurrent investigational commercial drug therapy treatment DCIS invasive breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>